Sengul C. Ozdek, Sibel Eryigit, Berati Hasanreisoglu (Ankara, Turkey)

Purpose:

To determine if PRN Bevacizumab can maintain the visual acuity (VA) gained with loading Ranibizumab for wet ARMD.

Methods:

The reports of patients with wet ARMD treated with 3 monthly Ranibizumab followed by PRN Bevacizumab were reviewed retrospectively. VA and central foveal thickness (CFT) in OCT at the beginning were compared with those after loading and at the last visit.

Results:

54 eyes were involved in the study. Mean follow-up was 6.3 months. Mean VA was 1.07 logMAR before treatment, increased to 0.91 at 3rd month, and 0.90 at the last visit. The mean CFT in OCT was 324.8±93.1 microns at the beginning, 256.3±35.4 at the 3rd month, and 243.4±54.1 at the last visit.

Conclusions:

The results confirm that PRN Bevacizumab treatment can maintain the initial VA increase gained with Ranibizumab loading dose.

Take home message:  

The results confirm that PRN Bevacizumab treatment can maintain the initial VA increase gained with Ranibizumab loading dose.